Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Asher Chanan-Khan, MD, Jeffrey Wolf, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Debbie Manfredi, Kelvin P. Lee, MD, Kena C Miller, NP, Robin Guild, Sybil Zildjian, MPH, Albert Qin, MD, Ph.D., James O'Leary, MD, Robert Vescio, MD

Blood (2009) 114 (22): 2883.

https://doi.org/10.1182/blood.V114.22.2883.2883

Published: 2009

Journal Articles

Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM).

Rachid Baz, Mohamad Hussein, MD, Daniel J. Lebovic, MD, Elizabeth Finley-Oliver, RN, Mehul P Patel, MB, BS, Hong Liu, Kena C Miller, NP, Margaret Wood, Kelvin P. Lee, MD, Asher Chanan-Khan, MD

Blood (2009) 114 (22): 3868.

https://doi.org/10.1182/blood.V114.22.3868.3868

Published: 2009

Journal Articles

Geographical Variation Shows Differences in Disease Characteristics Among Patients with Multiple Myeloma.

Sikander Ailawadhi, MD, Michael Keng, MD, Ann Mohrbacher, MD, Eddie Thara, MD, Dongyun Yang, PhD, Taimur Sher, MD, Mehul P Patel, MB, BS, Kena C Miller, NP, Susan Groshen, PhD, Asher A. Chanan-Khan, MD

Blood (2009) 114 (22): 4895.

https://doi.org/10.1182/blood.V114.22.4895.4895

Published: 2009

Journal Articles

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma.

Asher A. Chanan-Khan, MD, Kena C. Miller, NP, Dawn DePaolo, Swaminathan Padmanabhan, MD, Amy Whitworth, Sikander Ailawadhi, MD, Kelvin Lee, MD, Myron S. Czuczman, MD

Blood (2007) 110 (11): 3614.

https://doi.org/10.1182/blood.V110.11.3614.3614

Published: 2007

Journal Articles

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Asher A. Chanan-Khan, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Kenneth C. Anderson, MD, Kelvin Lee, MD, Dawn DePaolo, Kena C. Miller, NP, Sybil Zildjian, Robert J. Fram, MD, Qin

Blood (2007) 110 (11): 1174.

https://doi.org/10.1182/blood.V110.11.1174.1174

Published: 2007

Journal Articles

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma.

Dawn DePaolo, Kena C. Miller, NP, Amy Whitworth, Alice Mohr, NP, Terry L. Mashtare, Jr., Gregory Wilding, Sikander Ailawadhi, MD, Swaminathan Padmanabhan, MD, Asher A. Chanan-Khan, MD

Blood (2007) 110 (11): 4844.

https://doi.org/10.1182/blood.V110.11.4844.4844

Published: 2007

Journal Articles

Weight Adjusted Low-Dose Warfarin Decreases the Incidence of Thalidomide (T) Associated Venous Thromboembolism (VTE) in Patients (pts) with Multiple Myeloma (MM) and Waldenstroms Macroglobulinemia (WM).

Kena C. Miller, NP, Rami Manochakian, Swaminathan Padmanabhan, MD, Jean-Gabriel Coignet, Laurie Musial, Dawn DePaolo, Asher Alban Chanan-Khan, MD

Blood (2006) 108 (11): 4101.

https://doi.org/10.1182/blood.V108.11.4101.4101

Published: 2006

Journal Articles

Co-Expression of CD38 with Zap-70 Is Predictive of Treatment Intervention in Patients (pts) with Early Stage Chronic Lymphocytic Leukemia (CLL).

Jean-Gabriel Coignet, Swaminathan Padmanabhan, MD, Rami Manochakian, MD, Kena C. Miller, NP, Paul Wallace, Ph.D., AnneMarie Block, Ph.D., Asher Alban Chanan-Khan, MD

Blood (2006) 108 (11): 4945.

https://doi.org/10.1182/blood.V108.11.4945.4945

Published: 2006

Journal Articles

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial.

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Patricia Marshall, Swaminathan Padmanabhan, MD, William Brady, Zale P. Bernstein, MD, Paul Wallace, MD, Myron S. Czuczman, MD

Blood (2005) 106 (11): 2974.

https://doi.org/10.1182/blood.V106.11.2974.2974

Published: 2005

Journal Articles

In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Asher Alban Chanan-Khan, MD, Swaminathan Padmanabhan, MD, Kena C. Miller, NP, Paula Pera, Laurie DiMiceli, Noreen Ersing, Paul Wallace, MD, Michael Rickert, Carl Porter, MD

Blood (2005) 106 (11): 2975.

https://doi.org/10.1182/blood.V106.11.2975.2975

Published: 2005

Journal Articles

Characterization of IMiDs (Immunomodulating Agents) Induced “Flare Reaction” in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.

Laurie DiMiceli, RN, Kena C. Miller, NP, Michael Rickert, Paul Wallace, MD, Patricia Marshall, Dawn DePaolo, Swaminathan Padmanabhan, MD, Beverly Landrigan, RN, Asher A. Chanan-Khan, MD

Blood (2005) 106 (11): 5049.

https://doi.org/10.1182/blood.V106.11.5049.5049

Published: 2005

Journal Articles

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Laurie DiMiceli, Swaminathan Padmanabhan, MD, David Lawrence, Zale P. Bernstein, MD, Kenichi Takeshita, MD, David Spaner, Paul Wallace, MD, Catriona Byrne, Cynthia Crystal, Myron S. Czuczman, MD

Blood (2005) 106 (11): 447.

https://doi.org/10.1182/blood.V106.11.447.447

Published: 2005

Journal Articles

A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results.

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Philip McCarthy, MD, Laurie A. DiMiceli, Jihnee Yu, Zale P. Bernstein, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 2421.

https://doi.org/10.1182/blood.V104.11.2421.2421

Published: 2004

Journal Articles

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Philip McCarthy, MD, Alexandra Koryzna, RN, Peter Kouides, MD, Kathleen Donohue, Alice Mohr, NP, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3463.

https://doi.org/10.1182/blood.V104.11.3463.3463

Published: 2004

NARROW

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Evaluation of Single Agent Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma (NDMM).

Geographical Variation Shows Differences in Disease Characteristics Among Patients with Multiple Myeloma.

Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT) for the Treatment of Previously Untreated Multiple Myeloma.

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma.

Weight Adjusted Low-Dose Warfarin Decreases the Incidence of Thalidomide (T) Associated Venous Thromboembolism (VTE) in Patients (pts) with Multiple Myeloma (MM) and Waldenstroms Macroglobulinemia (WM).

Co-Expression of CD38 with Zap-70 Is Predictive of Treatment Intervention in Patients (pts) with Early Stage Chronic Lymphocytic Leukemia (CLL).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Preliminary Results of a Phase I/II Clinical Trial.

In Vivo Evaluation of Immunomodulating Effects of Lenalidomide (L) on Tumor Cell Microenvironment as a Possible Underlying Mechanism of the Antitumor Effects Observed in Patients (pts) with Chronic Lymphocytic Leukemia (CLL).

Characterization of IMiDs (Immunomodulating Agents) Induced “Flare Reaction” in Patients with Chronic Lymphocytic Leukemia (CLL) and Correlation with Changes in Serum Cytokine Levels.

Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

A Phase II Study of Velcade (V), Doxil (D) in Combination with Low-Dose Thalidomide (T) as Salvage Therapy for Patients (pts) with Relapsed (rel) or Refractory (ref) Multiple Myeloma (MM) and Waldenstorm Macroglobulinemia (WM): Encouraging Preliminary Results.

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only